A Study of a Vaccine in Combination With Beta-glucan in People With Neuroblastoma

This study is testing whether a vaccine combined with beta-glucan (a natural immune-stimulating compound) can help prevent neuroblastoma — a childhood cancer — from returning in children and young adults who have achieved remission after intensive treatment. **You may be eligible if...** - You have been diagnosed with high-risk neuroblastoma as defined by international criteria (e.g., spread beyond the primary site, MYCN gene amplification) - You are in first complete remission (at least 6 months after starting immunotherapy with anti-GD2) or in second or subsequent complete remission - You meet standard performance and organ function criteria **You may NOT be eligible if...** - You have active (not in remission) neuroblastoma - You have serious organ dysfunction or active infections - You have had prior bone marrow transplant that would prevent participation - You have had certain specific prior treatments that conflict with this protocol Talk to your doctor to see if this trial is right for you.